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ABSTRACT 
 
Background: Leukemia is cancer of the blood or bone marrow, characterized by an unusual 
increase in white blood cells. It is the sixth most common malignancy in the country in both 
males and females. The aim of this study was to document some epidemiological features of 
leukemia in the Northwest of Iran. 
Methods: The study subjects (n=669, including 377 males and 292 females) comprised all 
leukemia cases registered/notified to the clinical and pathology centers of Tabriz and Ardebil 
cities, from 2003 to 2006. All patients were classified using the ICD-10 based coding system 
(C91-C95, C77 and C42). Ninety-five percent confidence intervals were calculated to assess 
the statistical significance of the data. 
Results: Annual incidence of leukemia was 3.7 [95% CI: 3.3–4.0] and 4.9 [95% CI: 4.2–5.6] 
per 100 000 population in Tabriz and Ardebil, respectively, with an overall case fatality rate 
of 13.5 percent [95% CI: 10.8–16.0]. The sex ratio (male/female) was 1.23. Myeloid leukemia 
(C92) and Hematopoetic and Reticuloendothelial system (C42) accounted proportionally for 
more than 47 percent of cases in the region. Over the study period, the annual occurrence of 
leukemia in the region increased from 3.9 [95% CI: 3.4–4.5] to 4.1 [95% CI: 3.5–4.6] per 100 
000 population (P>0.1).  
Conclusions- The data from this cross-sectional study of leukemia in the North-West of Iran 
may be used as the baseline information to establish a population-based registry of hema-
tologic disorders in the area for health care and research purposes. However, more investiga-
tions are needed to develop effective strategies to control the relevant disorders in high-risk 
groups. 
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Introduction 
Leukemia is the cancer of the blood or 
bone marrow, characterized by an unusual 
increase in white blood cells.  Although 
different types of leukemia can occur at 
any age, adults age 60+ are more likely to 
develop the disease than younger people 
are. The most common types in adults are 
Acute Myelogenous Leukemia (AML) and 
Chronic Lymphocytic Leukemia (CLL). 
Acute Lymphocytic Leukemia (ALL) is 
the most common form of leukemia in 
children. Lifetime probability of develop-
ing any leukemia for adults is 1-2%. This 
probability varies by subtypes of leukemia: 
CLL=0.56%, Chronic Myelogenous Leu-
kemia (CML) = 0.20 %, ALL= 0.06%, and 
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AML= 0.46% (1-4). Hematologic cancers 
are the sixth most common malignancies in 
Iran both in males and in females (5). 
The aim of this study was to document 
some epidemiological features of leukemia 
in the Northwest of Iran and to provide 
base line information to set up a regional 
registry of hematology and oncology.  
 
Materials and Methods 
 
In this cross sectional study, medical his-
tory of 669 cases (including 377 males and 
292 females of leukemia between 2003 and 
2006 in Northwest of Iran were studied. 
All subjects were registered/notified to the 
clinical and pathology centers of Tabriz 
and Ardebil cities, two major cities in the 
Northwest of Iran. Patients were classified 
using the ICD-10 based coding system 
)(C91-C95, C77, and C42). Data collected 
included age, gender, date of diagnosis, 
treatment, residence status, and outcome. 
Incidence rates and descriptive indicators 
(i.e. case fatality rate and sex ratio, etc) 
were calculated to document the epidemi-
ological features of the leukemia in the re-
gion. Ninety-five percent confidence inter-
vals were calculated to assess the statistical 
significance of the data. 
 
Results 
 
Annual occurrence of leukemia disorders 
in the Northwest of Iran is presented in 
Table 1. Annual incidence of leukemia was 
3.7 [95% CI: 3.3–4.0] and 4.9 [95% CI: 
4.2–5.6] per 100 000 population in Tabriz 
and Ardebil, respectively, with an overall 
annual occurrence of 3.97 [95% CI: 3.66–
4.28] for the whole region. The sex ratio 
(male/female) was 1.2. Myeloid leukemia 
(C92) and Hematopoetic and Reticuloen-
dothelial system (C42) accounted propor-
tionally for more than 47 percent of cases 
in the region. Total case fatality rate was 
13.5% [95% CI: 10.8–16.0].  
Over the study period, the annual occur-
rence of leukemia in the region increased 
from 3.9 [95% CI: 3.4–4.5] to 4.1 [95% 
CI: 3.5–4.6] per 100 000 population 
(P>0.1).  
 
Discussion 
 
This investigation was a cross sectional 
study designed to describe some of epide-
miological features of leukemia in the 
Northwest of Iran with population cover-
age of 4-5 millions. This study was con-
ducted to provide the base line information 
to set up the first regional registry of He-
matology & Oncology in Iran. Such basic 
data are essential for planning health care 
services, for screening programs and to 
identify clues to the etiology of hema-
tologic malignancies. 
In this study, 669 cases of some types of 
leukemia were identified in the Northwest 
of Iran with an average population size of 
4855034 in the area.  
Our findings on the incidence of leukemia 
indicated that the occurrence of leukemia 
among males was much higher than fe-
males. The incidence rates did also in-
crease by age groups. These findings were 
almost similar to the research data reported 
previously (1-4, 6-12).  
Despite some limitations, our study pro-
vides basic information on the magnitude 
and spectrum of leukemia in the region. 
The findings may also indicate an opportu-
nity for future epidemiologic and etiologic 
investigations as well as accelerate the de-
velopment of new control strategies in the 
population. 
In conclusion, the data from this cross-
sectional study of leukemia in the North-
west of Iran may be used as the baseline 
information to establish a population-based 
registry of hematologic disorders in the 
area for health care and research purposes. 
However, more investigations are needed 
to develop effective strategies to control 
the relevant disorders in high-risk groups. 
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Table 1: Occurrence of leukemia disorders in the Northwest of Iran 
 
 
Parameters      Annual Rate   
Confidence 
Interval 
      n  (per 100 000)    (95%) 
Gender           
Male    377  4.34    (3.67,5.01) 
Female    292  3.5    (2.94,4.06) 
Age Groups           
Less Than 15 (Years)    30  0.63    (0.45,0.81) 
15-29    139  0.78    (0.72,0.84) 
30-44    99  2.98    (1.79,4.17) 
45-59    110  5.88    (1.69,10.07) 
60 And More    193  13.67    (0.77,26.57) 
Unknown    98  -     
Types           
C91 (Lymphoid Leukemia)    195  1.16    (1.07,1.25) 
C92 (Myeloid Leukemia)    230  1.37    (1.26,1.48) 
C93 (Monocytic Leukemia)    6  0.64    (0.59,0.69) 
C94 (Other Leukemia Of Specified Cell 
Type)  16  0.59    (0.54,0.64) 
C95 (Leukemia Of Unspecified Cell Type)  17  0.15    (0.14,0.16) 
C77 (Secondary And Unspecified     83  0.49    (0.45,0.53) 
Malignant Neoplasm Of Lymph Nodes)          
C42 (Hematopoetic And Re-
ticuloendothelial System)  102  0.61    (0.56,0.66) 
Unknown    20  0.12    (0.11,0.13) 
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